Navigation Links
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Date:12/22/2009

PITTSBURGH, Dec. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.

Mylan President Heather Bresch commented: "This New Drug Application represents another successful innovation by Matrix in the fight against HIV/AIDS. Our HIV/AIDS antiretroviral (ARV) franchise continues to grow and to bring more affordable, high quality medications to patients in the developing world. We are extremely pleased to be able to add these new dosages to the basket of treatment options currently available to the medical community, and to expand our portfolio of products for treating pediatric HIV/AIDS."

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (nNRTI) that has been found to be effective in many combination regimens for the treatment of HIV infection, both in treatment-naive and in treatment-experienced individuals.

The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. Although existing patents or exclusivity prevent its marketing in the U.S., the product will be eligible for purchase outside the U.S. in many developing countries.

Matrix's wide range of ARV products includes active pharmaceutical ingredients and first- and second-line finished doses. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per person of effective therapies. Approximately 30%
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Added to NASDAQ-100 Index
2. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
3. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
6. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
8. The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
9. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
10. CareCentrix Receives URAC Health Utilization Management Accreditation
11. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... -- Cipla, a global pharmaceutical company which uses technology and ... today announced that its UK arm, Cipla EU has ... InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction ... $550 million and will be an all cash transaction. ... million for the year ended Dec 2014 and over ...
(Date:9/3/2015)... -- Report Details What can be expected ... to grow at the fastest rates? Visiongain,s brand new ... trends, opportunities and prospects there. Our 205-page ... most lucrative areas in the industry and the future ... sales at overall world market and regional level. You ...
(Date:9/3/2015)... a population of more than 1 billion, China is ... largest potential market for goods and services. In the ... economies in the average rate of growth in real ... an in vitro diagnostics (IVD) market, China trails only ... European countries, and Japan. China represents one of the ...
Breaking Medicine Technology:Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... MedMined(TM) services from Cardinal Health Equip Hospitals to Measure ... ... Sharing, DUBLIN, Ohio, April 29 Cardinal Health, a,global provider ... care, today announced a new benchmarking tool from,MedMined(TM) services that allows ...
... Opening celebrated with inaugural Symposium on Biofilms, ... 29 ,BASF today announced the official launch ... University. The Advanced Research Initiative at,Harvard University ... specifically to drive new frontiers of scientific,discovery. ...
Cached Medicine Technology:Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 2Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 3Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 4BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 2BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 3
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... and the surrounding communities, is launching a charity effort to provide for the ... referred to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships ... of cancer treatments and recover their mobility, strength, and range of motion following ...
(Date:9/4/2015)... ... September 04, 2015 , ... San ... available at CitiDent. CEREC is a newer method for creating restorations through innovative ... patients by eliminating the need for multiple appointments, CEREC produces restorations with total ...
(Date:9/4/2015)... ... 04, 2015 , ... Many consumers are looking for a quick and convenient way to produce ... patent-pending K Med Cups provide a quick and simple way to brew a hot cup ... or cough. As a result, they enhance comfort and health. The invention features a novel ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... Boston and Harvard Medical School will lead the efforts ... Office of the National Coordinator for Health Information Technology ... (HHS) to support research and development of a new ... of four awarded through the Strategic Health IT Advanced ...
... April 8, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... for Thursday, April 15, 2 3 p.m. Eastern ... Lawler & Lawler, with more than 30 years of ...
... an institute you can,t disparage." Especially, a new Tel Aviv ... prevent fatal strokes in men. The first study of ... its association with stroke risk,Prof. Uri Goldbourt of Tel Aviv ... in marriage and the likelihood that a man will die ...
... ... management client since 1994, was recently ranked among the top 100 hospitals in the United ... Top Hospitals® National Benchmarks Study were announced in the March 29 issue of Modern Healthcare. ... Brentwood, Tenn. (PRWEB) ...
... finds , THURSDAY, April 8 (HealthDay News) -- Although ... medical records as a major advance over the old paper ... haven,t significantly boosted patient life spans or lowered costs. ... health record adoption, and there,s little evidence for how best ...
... can benefit people with the disease , THURSDAY, April 8 ... diabetes in mice using a new vaccine technology that appears ... disease. , "The body has built-in mechanisms that try to ... can be [used] to selectively blunt an immune response without ...
Cached Medicine News:Health News:Boston researchers lead $15 million federal research grant to support advancement of health IT 2Health News:ACS Webinar focuses on immigration law for scientific professionals 2Health News:Different strokes for married folks? 2Health News:Thomson Reuters Names QHR Management Client to 100 Top Hospitals List - Wooster Community Hospital Honored for Third Consecutive Year 2Health News:Vaccine Reverses Type 1 Diabetes in Mice 2Health News:Vaccine Reverses Type 1 Diabetes in Mice 3
Hertel exophthalmometer...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
The first daily disposable lens affordable enough for full time wear....
... UltraPulse system's capability to quickly deliver up ... pulse allows for powerful single-pulse ablation. This ... system the coldest and cleanest CO2 surgical ... is combined with the independent adjustment of ...
Medicine Products: